avanti极性脂质/D-(+)-海藻糖6,6-二苯甲酸酯/890808P-25mg

价格
¥28425.00
货号:890808P-25mg
浏览量:127
品牌:avanti polar lipids
服务
全国联保
正品保证
正规发票
签订合同
商品描述

890808 | 22:0 Trehalose

D-(+)-trehalose 6,6"-dibehenate

22:0 Trehalose
Info

22:0 Trehalose

D-(+)-trehalose 6,6"-dibehenate

Incorporation of the glycolipid trehalose 6,6"-dibehenate (TDB) into cationic liposomes composed of the quaternary ammonium compound dimethyldioctadecylammonium (DDA) produce an adjuvant system which induces a powerful cell-mediated immune response and a strong antibody response, desirable for a high number of disease targets.

Data
Hygroscopic
No
Light Sensitive
No
Molecular Formula
C56H106O13
Percent Composition
C 68.12%, H 10.82%, O 21.06%
Purity
>99%
Stability
1 Years
Storage Temperature
-20°C
CAS Number
66758-35-8 CAS Registry Number is a Registered Trademark of the American Chemical Society
FormulaWeight
987.433
Exact Mass
986.763
Synonyms
TDB6,6'-didocosanoyl-α,α'-trehalose
Downloads
  • ChemDraw File
  • 3D Structure
  • Structure
  • Brochure
  • Safety Data Sheet
References

Teng X, Tian M, Li J, Tan S, Yuan X, Yu Q, Jing Y, Zhang Z, Yue T, Zhou L, Fan X. Immunogenicity and protective efficacy of DMT liposome-adjuvanted tuberculosis subunit CTT3H vaccine. Hum Vaccin Immunother. 2015;11(6):1456-64. doi: 10.1080/21645515.2015.1037057. PMID: 25905680; PMCID: PMC4514263.

PubMed ID: 25905680

Rose F, Wern JE, Ingvarsson PT, van de Weert M, Andersen P, Follmann F, Foged C. Engineering of a novel adjuvant based on lipid-polymer hybrid nanoparticles: A quality-by-design approach. J Control Release. 2015 Jul 28;210:48-57. doi: 10.1016/j.jconrel.2015.05.004. Epub 2015 May 6. PMID: 25957906.

PubMed ID: 25957906

Derrick SC, Yabe I, Morris S, Cowley S. Induction of Unconventional T Cells by a Mutant Mycobacterium bovis BCG Strain Formulated in Cationic Liposomes Correlates with Protection against Mycobacterium tuberculosis Infections of Immunocompromised Mice. Clin Vaccine Immunol. 2016 Jul 5;23(7):638-47. doi: 10.1128/CVI.00232-16. PMID: 27226281; PMCID: PMC4933783.

PubMed ID: 27226281

Larrouy-Maumus G, Layre E, Clark S, Prandi J, Rayner E, Lepore M, de Libero G, Williams A, Puzo G, Gilleron M. Protective efficacy of a lipid antigen vaccine in a guinea pig model of tuberculosis. Vaccine. 2017 Mar 7;35(10):1395-1402. doi: 10.1016/j.vaccine.2017.01.079. Epub 2017 Feb 9. PMID: 28190740.

PubMed ID: 28190740

Hansen M, Peltier J, Killy B, Amin B, Bodendorfer B, Härtlova A, Uebel S, Bosmann M, Hofmann J, Büttner C, Ekici AB, Kuttke M, Franzyk H, Foged C, Beer-Hammer S, Schabbauer G, Trost M, Lang R. Macrophage phosphoproteome analysis reveals MINCLE-dependent and -independent mycobacterial cord factor signaling. Mol Cell Proteomics. 2019 Jan 11. pii: mcp.RA118.000929. doi: 10.1074/mcp.RA118.000929. [Epub ahead of print]

PubMed ID: 30635358

Fomsgaard, A., Karlsson, I., Gram, G., Schou, C., Tang, S., Bang, P., Kromann, I., Andersen, P., Andreasen, L.V. (2011) Development and preclinical safety evaluation of a new therapeutic HIV-1 vaccine based on 18 T-cell minimal epitope peptides applying a novel cationic adjuvant CAF01. Vaccine. 29:7067-74.

PubMed ID: 21767590

Nordly, P., Agger, E.M., Andersen, P., Nielsen, H.M., Foged, C. (2011) Incorporation of the TLR4 agonist monophosphoryl lipid A into the bilayer of DDA/TDB liposomes: physico-chemical characterization and induction of CD8+ T-cell responses in vivo. Pharm Res. 28:553-62.

PubMed ID: 21042837

Gram, G.J., Karlsson, I., Agger, E.M., Andersen, P., Fomsgaard, A. (2009) A novel liposome-based adjuvant CAF01 for induction of CD8(+) cytotoxic T-lymphocytes (CTL) to HIV-1 minimal CTL peptides in HLA-A*0201 transgenic mice. PLoS One. 4:e6950.

PubMed ID: 19759892

Davidsen, J., Rosenkrands, I., Christensen, D., Vangala, A., Kirby, D., Perrie, Y., Agger, E.M., Andersen, P. (2005) Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6"-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responses. Biochim Biophys Acta. 1718:22-31.

PubMed ID: 16321607
Certificates of Analysis
  • Certificate of Analysis(Lot No. 890808P-25MG-A-017and 6351PJA017)
  • Certificate of Analysis(Lot No. 890808P-5MG-A-017and 6351PHA017)
  • Certificate of Analysis(Lot No. 890808P-25MG-B-017and 6351PJB017)
  • Certificate of Analysis(Lot No. 890808P-5MG-B-017and 6351PHB017)
  • Certificate of Analysis(Lot No. 890808P-5MG-C-017and 6351PHC017)
  • Certificate of Analysis(Lot No. 890808P-25MG-C-017and 6351PJC017)
  • Certificate of Analysis(Lot No. 890808P-5MG-D-017and 6351PHD017)
  • Certificate of Analysis(Lot No. 890808P-5MG-E-017and 6351PHE017)
  • Certificate of Analysis(Lot No. 890808P-5MG-F-017and 6351PHF017)
  • Certificate of Analysis(Lot No. 890808P-25MG-D-017and 6351PJD017)
Base Price:${originalprice|money}
Custom Packaging:(${concentration} @$4.00/ea. + $100)${custompackagingtotal|money}
Packaging:${concentration}
Item Total:${totalprice|money}
(Sales Tax may apply)
Please select an option above.
${sku} - ${concentration}
美国Avanti Polar Lipids Inc www.avantilipids.com Avanti Polar Lipids Inc, 是美国著名的磷脂类产品的生产商,该公司主要为各种制药厂和研究机构提供从毫克级到公斤级乃至吨级的磷脂类和甾体类中间体和试剂。 Avanti Polar Lipids.公司为世界范围内的研究机构和制药公司提供 1000 种以上脂类产品,由于其产品的高纯度而享誉全球, For 40 years, Avanti Polar Lipids, Inc. has been supplying lipids to researchers and pharmaceutical companies around the world. Not only has the range of products grown every year but so has Avanti’s unique reputation for purity. This brings us the satisfaction of our clients and the envy of our competitors. Avanti’s clients order from a stock of over 1,000 lipids at affordable prices. They enjoy working with our dedicated Customer Service representatives and benefit from our informed Technical Support team. Research clients are encouraged to contact us about custom synthesis of products not listed in our catalog. We are pleased to offer our Pharmaceutical clients products which follow cGMP guidelines. Avanti’s selection of chemicals and range of services for Research and Pharmaceutical applications include • Analytical Services • Bioactive Lipids • Biotinylated Lipids • Cationic Lipids • L-threo-Lac Cer (Caveolar Uptake Inhibitor) • Cholesterol, Plant & Animal Derived • Coenzyme A, Fluorescent & Fatty Acyl Derivatives • Deuterium Labeled Phospholipids & Sphingolipids • Eicosanoids (synthetic) • Extrusion Equipment for Liposome Preparation • Fluorescent Phospholipids & Sphingolipids • Glycosylated & Phosphorylated Sphingolipids • Kdo2 Lipid A (TLR 4 Agonist) • PHAD™ Synthetic Vaccine Adjuvant • Lipid Formulation • LPA, Cyclic LPA & LPA Analogues • LIPID MAPS Mass Spec Standards • Oxidized Lipids • Sterols, Oxysterols, Deuterated & Fluorescent Sterols • PIP’s, Polyunsaturated PIP3, & Fluorescent PIP’s • Phospholipids & Sphingolipids • Polymerizable Lipids, PEG-Lipids & Functionalized PEG’s • Prostaglandins (synthetic) • S1P/LPA Receptor Selective Agonists & Antagonists • Sphingosyl PE & PI